We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition.
- Authors
Beykou, Melina; Arias-Garcia, Mar; Roumeliotis, Theodoros I.; Choudhary, Jyoti S.; Moser, Nicolas; Georgiou, Pantelis; Bakal, Chris
- Abstract
When used in combination with hormone treatment, Palbociclib prolongs progression-free survival of patients with hormone receptor positive breast cancer. Mechanistically, Palbociclib inhibits CDK4/6 activity but the basis for differing sensitivity of cancer to Palbociclib is poorly understood. A common observation in a subset of Triple Negative Breast Cancers (TNBCs) is that prolonged CDK4/6 inhibition can engage a senescence-like state where cells exit the cell cycle, whilst, remaining metabolically active. To better understand the senescence-like cell state which arises after Palbociclib treatment we used mass spectrometry to quantify the proteome, phosphoproteome, and secretome of Palbociclib-treated MDA-MB-231 TNBC cells. We observed altered levels of cell cycle regulators, immune response, and key senescence markers upon Palbociclib treatment. These datasets provide a starting point for the derivation of biomarkers which could inform the future use CDK4/6 inhibitors in TNBC subtypes and guide the development of potential combination therapies. Measurement(s) Proteomic Profiling Technology Type(s) Liquid Chromatography Mass Spectrometry Factor Type(s) Palbociclib dosage Sample Characteristic - Organism Homo sapiens Sample Characteristic - Environment cell culture
- Subjects
TRIPLE-negative breast cancer; HORMONE receptor positive breast cancer; LIQUID chromatography-mass spectrometry; PROTEOMICS; CYCLIN-dependent kinase inhibitors; CANCER cells
- Publication
Scientific Data, 2022, Vol 9, Issue 1, p1
- ISSN
2052-4463
- Publication type
Article
- DOI
10.1038/s41597-022-01512-1